FDA approves Atebrioz, the third ever treatment for ultra rare stone man disease FOP

Fibrodysplasia ossificans progressiva is a genetic disease in which the body builds a second skeleton where none should exist. A mutation in activin A receptor-type 1, the gene that helps govern new bone growth, causes connective tissues such as muscle, tendons and ligaments to gradually turn into bone. The result is progressive loss of movement, deformity, severe disability and early death. The condition is extremely rare. It affects roughly 300 people in the United States and about 900 people worldwide, and until recently families had very little to work with beyond pain management and physical therapy.

That landscape has shifted quickly. The first approved therapy for the disease, Ipsen's Sohonos (palovarotene), reached the market in 2023 after a difficult regulatory path. A second option, Regeneron's Pasatru (garetosmab-grts), was approved on August 19, 2026. On September 25, 2026, the U.S. Food and Drug Administration approved a third treatment, Atebrioz (zilurgisertib), a once-daily oral tablet developed by Incyte and licensed to Mirum Pharmaceuticals for worldwide development and commercialization.

Atebrioz is an activin receptor-like kinase 2, or ALK2, inhibitor. In people living with fibrodysplasia ossificans progressiva, pathogenic variants in the ACVR1 gene cause abnormal ALK2 activation, which drives the formation of bone in soft tissues, a process called heterotopic ossification. By targeting that pathway, the drug aims at the biology at the center of the disease rather than at its symptoms. It is approved for adults and pediatric patients aged 12 years and older, and the recommended starting dosage is 100 mg taken orally once daily with or without food.

The approval rests on a randomized, double-blind, placebo-controlled trial, NCT05090891, that has become the central evidence base for the drug. Sixty-three patients with fibrodysplasia ossificans progressiva were assigned to receive either Atebrioz 100 mg or placebo once daily for 24 weeks, followed by a single-arm, open-label extension period of 292 weeks during which all participants received Atebrioz 100 mg daily. Efficacy was measured with whole body CT scans, tracking the change from baseline in the volume of total new heterotopic ossification.

Key Facts

The FDA said in its approval notice on September 25, 2026 that Atebrioz tablets are indicated to reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva. The agency based the effectiveness finding on the change from baseline in the volume of total new heterotopic ossification compared with placebo during the double-blind period. At Week 24, the group receiving Atebrioz had an average decrease of 3.2 cm3 in that volume, while the placebo group had an average increase of 24.6 cm3.

Reuters reported on September 25, 2026 that the FDA approved Mirum's once-daily pill for the rare bone disorder and that the decision makes Atebrioz the third marketed therapy for the condition. The news organization noted that the drug is an oral ALK2 inhibitor developed by Incyte and licensed to Mirum, and that Mirum expects the product to launch in the United States in October. Reuters also reported that the FDA granted Incyte a Rare Pediatric Disease Priority Review Voucher upon approval.

Mirum and Incyte said in a joint announcement on September 25, 2026 that treatment effects were maintained through Week 48 of the open-label extension and that the drug was generally well tolerated, with most adverse events rated mild or moderate and no adverse events leading to treatment discontinuation or dose reduction. The companies also disclosed that 81 percent fewer patients developed new heterotopic ossification lesions, a difference that carried a p value of 0.0986, and a 99 percent reduction in total new heterotopic ossification lesion volume at Week 24 with a nominal p value below 0.0001. Chris Peetz, chief executive officer at Mirum, called the approval an important milestone for people living with the disease.

Healio reported on September 25, 2026 that the approval covers patients aged 12 years or older and that the third approved treatment joins garetosmab-grts (Pasatru, Regeneron) and palovarotene (Sohonos, Ipsen). The FDA listed the most common side effects as headache, joint pain, upper respiratory tract infection, nosebleeds and nausea. The agency also warned that Atebrioz can cause fetal harm based on animal data, so patients of reproductive potential should use effective contraception. The drug received fast track, priority review and orphan drug designation for this indication.

Commercial access will run through Mirum Access Plus, the company's patient support program. Mirum said eligible patients are expected to pay as little as $0 per month, and that U.S. commercial availability is expected in October 2026. Outside the United States, a marketing authorization application for zilurgisertib is under review by the European Medicines Agency.

Analysis

What this really means is that fibrodysplasia ossificans progressiva has moved, in the space of roughly three years, from a disease with no approved targeted therapy to one with three. That is an unusual speed of change for an ultra-rare condition with a population measured in the hundreds, and it reflects a convergence of factors: a well-understood genetic driver in ACVR1 and ALK2 signaling, a rare disease company willing to run a global program, and a regulator that has leaned on expedited tools such as fast track, priority review and orphan drug designation.

The trial numbers deserve a careful reading rather than a headline skim. The 3.2 cm3 decrease on Atebrioz against a 24.6 cm3 increase on placebo is the figure the FDA used as the basis for effectiveness, and the divergence captures something important: in an untreated patient with active disease, new bone volume grew substantially over 24 weeks, while treated patients did not. The 99 percent reduction in total new heterotopic ossification lesion volume at Week 24 came with a nominal p value below 0.0001, but the 81 percent reduction in the number of patients who developed new lesions carried a p value of 0.0986, which is above the conventional threshold for statistical significance. Both figures came from the same 63-patient study, and small trials in rare diseases rarely deliver clean results on every endpoint.

The bigger picture here is that the competitive and clinical logic of FOP has changed from whether any drug can be approved to how the three available drugs will be sequenced, combined or chosen. Ipsen's palovarotene is a retinoic acid receptor gamma agonist; Regeneron's garetosmab-grts targets activin A; Mirum's zilurgisertib inhibits ALK2. Physicians treating a disease this rare now have to weigh mechanisms, dosing and tolerability, and the oral once-daily profile of Atebrioz is a practical differentiator against therapies that require other routes or regimens. None of the sources given here provides head-to-head data, so claims of superiority would be speculation.

The trial design also shapes what the label can say. Efficacy was established in Cohort 1 of the PROGRESS study, and the endpoint is a volume measurement on whole body CT scans rather than a functional measure such as mobility or flare frequency. That choice is defensible in a disease where new bone is the defining pathology, but it means the approval addresses the accumulation of heterotopic ossification rather than every consequence patients experience.

Why It Matters

For families in the United States, the practical effect is an additional oral option that the FDA cleared for patients as young as 12, with a company-run access program that Mirum says can bring out-of-pocket costs as low as $0 per month for eligible patients. In a disease where a single flare can permanently restrict a shoulder, a hip or a jaw, reducing the volume of new bone is not a cosmetic goal. Progressive heterotopic ossification leads to deformities, severe disability and early death, so any therapy that blunts the growth of new bone is aimed at the core of the condition.

The approval also matters for the regulatory template it reinforces. The FDA issued Incyte a Rare Pediatric Disease Priority Review Voucher, a transferable asset that can be used to speed review of a future application, and the agency granted fast track, priority review and orphan drug designation along the way. Those mechanisms are the machinery that makes development viable when the total patient population is roughly 300 people in the United States and about 900 worldwide, a market that cannot support a conventional commercial calculus.

There is also a broader scientific signal. Atebrioz validates ALK2 as a druggable target in humans. The same pathway is being studied well beyond FOP, and a clean approval with a defined mechanism gives researchers in related conditions a reason to look harder at activin and ALK2 signaling. The drug does not cure anything, and patients will still need monitoring and contraception counseling, but a validated target is a durable scientific asset.

Next Up

The PROGRESS program continues. Mirum and Incyte said Cohort 2, which covers children aged 6 to under 12, has completed enrollment, while Cohort 3, covering children aged 2 to under 12, is still enrolling. Data from those younger cohorts could eventually support an expansion of the label below the age of 12, which would matter for a disease in which the first episodes of heterotopic ossification often appear in childhood.

On the commercial and regulatory side, Mirum is expected to launch Atebrioz in the United States in October 2026, and the European Medicines Agency is reviewing a marketing authorization application for zilurgisertib. The next real test will be whether the three approved FOP therapies settle into distinct roles in practice, and whether payers and clinics build the infrastructure to deliver them to a patient population of a few hundred people scattered across the country.